Keywords: Capsugel, Pfizer, Kohlber Kravis Roberts, Tafamidis, Amyloid polyneuropathy, FDA, USA

Pfizer to sell Capsugel unit to KKR for $2.38 billion; FDA turns down tafamidis filing

Article | 05 April 2011

Print This

In line with recent guidance that it is viewing the sale of some non-core businesses, global drugs behemoth Pfizer (NYSE: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in